化合物 (+)-Cevimeline hydrochloride hemihydrate|T13460|TargetMol

(+)-Cevimeline hydrochloride hemihydrate

￥34800 25mg 起订

上海更新日期：2025-02-14

TargetMol中国（陶术生物）

VIP1年

联系人：邵小姐

手机：15002134094 拨打

邮箱：marketing@targetmol.cn

产品详情:

中文名称：: 化合物 (+)-Cevimeline hydrochloride hemihydrate

英文名称：: (+)-Cevimeline hydrochloride hemihydrate

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

产品类别：: 抑制剂

货号：: T13460

Product Introduction

Bioactivity

Name	(+)-Cevimeline hydrochloride hemihydrate
Description	(+)-Cevimeline hydrochloride hemihydrate ((+)-SNI-2011), a potent muscarinic receptor agonist, stands as a promising therapeutic candidate for treating xerostomia in Sjogren's syndrome. This compound has demonstrated a broad pharmacological profile across various systems including gastrointestinal, urinary, and reproductive, in animal models such as mice, rats, guinea pigs, rabbits, and dogs. Its metabolism was assessed in vitro using rat and dog liver microsomes, revealing that (+)-SNI-2011 is rapidly absorbed with peak plasma concentrations (Cmax) reached within one hour post-oral administration, followed by a decline with a half-life (t1/2) ranging from 0.4 to 1.1 hours. Bioavailability was recorded at 50% in rats and 30% in dogs. Metabolic analysis indicated species-specific differences, with rats producing both S- and N-oxidized metabolites and dogs only producing N-oxidized metabolites. Additionally, sex-based differences in pharmacokinetics were observed in rats but not in dogs. The in vitro study highlighted the involvement of cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) in the sulfoxidation and N-oxidation of SNI-2011, respectively, with CYP2D and CYP3A being primarily responsible for sulfoxidation in rat liver microsomes.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Keywords	(+)Cevimeline hydrochloride hemihydrate \| Cevimeline hydrochloride Hemihydrate \| AF102B hydrochloride Hemihydrate \| (+) Cevimeline hydrochloride hemihydrate \| SNI2011 \| SNI-2011 \| Cevimeline Hydrochloride \| SNI 2011 \| AF102B Hydrochloride

(+)-SNI-2011|||(+)-AF102B hydrochloride hemihydrate|TargetMol

查看全部

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	589.8595万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	中间体,天然产物,生物化工,化学试剂,生物技术服务